GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
RYLGX
Price
$86.94
Change
-$1.84 (-2.07%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs RYLGX

Header iconGFACX vs RYLGX Comparison
Open Charts GFACX vs RYLGXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Rydex S&P 500 Pure Growth A
Price$86.94
Change-$1.84 (-2.07%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs RYLGX Comparison Chart
Loading...
VS
GFACX vs. RYLGX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and RYLGX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. RYLGX (63.6M). GFACX (0.00) and RYLGX (0.00) have matching dividends . GFACX was incepted earlier than RYLGX: GFACX (24 years) vs RYLGX (20 years). RYLGX is a more actively managed with annual turnover of: 434.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than RYLGX: GFACX (250) vs RYLGX (2500). GFACX annual gain was more profitable for investors over the last year : 16.44 vs. RYLGX (14.82). GFACX return over 5 years is better than : 38.56 vs. RYLGX (30.52).
GFACXRYLGXGFACX / RYLGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years20 years-
Gain YTD14.98211.211134%
Front LoadN/AN/A-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets270B63.6M424,528%
Annual Yield % from dividends0.000.00-
Returns for 1 year16.4414.82111%
Returns for 3 years-11.08-15.2173%
Returns for 5 years38.5630.52126%
Returns for 10 years42.4661.6269%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc